Well -deserved summer vacation
The media have also contacted us to report on the situation of those affected. appeared in the Swiss family, and there was an exciting podcast on the Radio SRF , which is also available online. Here you will find the two articles.
In addition, we have already organized three events this year:
-On March 1st, the first We, The Patients event place in Zurich.
- Our general assembly followed on April 26th.
-On May 24th we carried out the We, The Patients cultivation workshop .
We hope that you liked these occasions and we would like to continue to offer more meetings in the future. We are already in the planning and will tell you more after the summer break.
On the last weekend in May we were also at the Buds and Beats Festival in Zurich Oerlikon. The two -day occasion was a success - there is a need for education, networking and exchange. We have held a lot of conversations, passed on information, made contacts and were very happy about how our community continues to grow.
Before we tackle new projects, we now need a break. From July to mid -August we make summer vacation . We are still available for you by email and on Telegram, but do not answer inquiries as regularly. There will also be no newsletter in July. We wish all members a nice summer time!
On August 1, the change in the law is also annoyed for the third time. A lot has improved, and some members have now received recipes and also the assumption of costs by the health insurance company. Nevertheless, very many still fight with the high costs - several hundred or even over a thousand francs per month, that simply cannot afford chronically ill people. It also often remains difficult to find a doctor who prescribe cannabis.
In an international comparison, Switzerland is better than some neighboring countries despite these challenges. This should be aware of this: We have the opportunity to refer to cannabis on a prescription in pharmacies - this is still not the case in many European countries. Nevertheless, the urgently needed support from the health insurance companies is still missing. This remains a big hurdle, because the health insurers demand studies that nobody wants to finance. Perhaps the announced legislation for legalization will open up a new opportunity to put the patients' problems into focus again.